Press releases
- Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
- Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
- Xeris to Participate in the Jefferies Global Healthcare Conference
- Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
- Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
More ▼
Key statistics
On Tuesday, Xeris Biopharma Holdings Inc (2B30:DUS) closed at 1.98, -11.58% below its 52-week high of 2.24, set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.93 |
---|---|
High | 1.98 |
Low | 1.93 |
Bid | 1.93 |
Offer | 2.00 |
Previous close | 1.93 |
Average volume | 190.00 |
---|---|
Shares outstanding | 148.26m |
Free float | 144.27m |
P/E (TTM) | -- |
Market cap | 312.82m USD |
EPS (TTM) | -0.4648 USD |
Data delayed at least 15 minutes, as of Jun 25 2024 18:30 BST.
More ▼